Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.
BACKGROUND
Elevated neutrophil to lymphocyte ratio (NLR) is linked with worse survival in many malignancies, whereas its association with pancreatic cancer (PC) remains unclear.


METHODS
We retrospectively reviewed 95 patients with locally advanced or metastatic PC receiving gemcitabine-based chemotherapy. The prognostic value of NLR was evaluated.


RESULTS
Elevated pretreatment NLR (> 5) was observed in 16 out of 89 eligible patients, which was identified as an independent prognostic factor for overall survival (OS). The median OS for patients with elevated and normal NLR were 2.4 months and 7.7 months, respectively (p < 0.001).


CONCLUSIONS
Elevated NLR is a predictor of shorter survival in patients with advanced PC.
An
Xin
X
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P. R. China.
Ding
Pei-Rong
PR
Li
Yu-Hong
YH
Wang
Feng-Hua
FH
Shi
Yan-Xia
YX
Wang
Zhi-Qiang
ZQ
He
You-Jian
YJ
Xu
Rui-Hua
RH
Jiang
Wen-Qi
WQ
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D015415:Biomarkers; D001772:Blood Cell Count; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000502:physiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009504:Neutrophils / Q000502:physiology*; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D013534:Survival; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D003841:Deoxycytidine; D000093542:Gemcitabine